- Home
- AWRE vs ANL Comparison
AWRE vs ANL Comparison
Compare AWRE & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AWRE
- ANL
- Stock Information
- Founded
- AWRE 1986
- ANL 2004
- Country
- AWRE United States
- ANL Cayman Islands
- Employees
- AWRE N/A
- ANL N/A
- Industry
- AWRE Computer Software: Prepackaged Software
- ANL
- Sector
- AWRE Technology
- ANL
- Exchange
- AWRE Nasdaq
- ANL Nasdaq
- Market Cap
- AWRE 56.1M
- ANL 61.8M
- IPO Year
- AWRE 1996
- ANL 2023
- Fundamental
- Price
- AWRE $2.45
- ANL $1.79
- Analyst Decision
- AWRE
- ANL Hold
- Analyst Count
- AWRE 0
- ANL 1
- Target Price
- AWRE N/A
- ANL N/A
- AVG Volume (30 Days)
- AWRE 35.2K
- ANL 11.3K
- Earning Date
- AWRE 10-29-2025
- ANL 10-21-2025
- Dividend Yield
- AWRE N/A
- ANL N/A
- EPS Growth
- AWRE N/A
- ANL N/A
- EPS
- AWRE N/A
- ANL N/A
- Revenue
- AWRE $16,146,999.00
- ANL N/A
- Revenue This Year
- AWRE N/A
- ANL N/A
- Revenue Next Year
- AWRE N/A
- ANL N/A
- P/E Ratio
- AWRE N/A
- ANL N/A
- Revenue Growth
- AWRE N/A
- ANL N/A
- 52 Week Low
- AWRE $1.35
- ANL $1.10
- 52 Week High
- AWRE $2.95
- ANL $3.89
- Technical
- Relative Strength Index (RSI)
- AWRE 47.11
- ANL 55.55
- Support Level
- AWRE $2.35
- ANL $1.70
- Resistance Level
- AWRE $2.84
- ANL $1.82
- Average True Range (ATR)
- AWRE 0.19
- ANL 0.09
- MACD
- AWRE -0.02
- ANL -0.00
- Stochastic Oscillator
- AWRE 26.55
- ANL 60.33
About AWRE Aware Inc.
Aware Inc is a provider of software and services to the biometrics industry. The company's software products are used in government and commercial biometrics systems to identify or authenticate people. The government applications of biometrics systems include border control, visa applicant screening, law enforcement, national defense, intelligence, secure credentialing, access control, and background checks. Its commercial applications include user authentication for login to mobile devices, computers, networks, and software programs, user authentication for financial transactions and purchases. Its geographical segments include the United States, the United Kingdom, and the Rest of the world, out of which it derives maximum revenue from United States.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.